Drugs / Interleukin-11
Interleukin-11
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT00493181 | Oct 2005 → Jan 2011 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00151125 | Jul 2004 → Dec 2007 | von Willebrand disease 1 | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00040521 | Apr 2002 → Oct 2003 | Crohn disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00004157 | Aug 2000 → Apr 2002 | breast cancer, gestational trophoblastic neoplasm, kidney cancer, lymphoma +4 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT02241031 Comparator | Sep 2014 → Sep 2016 | thrombocytopenia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06759636 Comparator | Feb 2025 → Apr 2026 overdue | chemotherapy-induced toxicity | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-28 | Lassen Therapeutics Inc. | Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody lassentherapeutics.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004157 ↗ |
| Known as | IL-11 | “Patients receive interleukin-11 (IL-11) subcutaneously (SQ) on days 1-10 and filgrastim (G-CSF) SQ on days 4-10.” NCT00004157 ↗ |
| Known as | Neumega | “Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC)” NCT00004157 ↗ |
| Known as | oprelvekin | “low-dose interleukin-11, (IL-11, oprelvekin, NeumegaTM)” NCT00493181 ↗ |
| Known as | Recombinant Human Interleukin-11 | “Recombinant Human Interleukin-11 (rhIL-11)” NCT00040521 ↗1“Recombinant Human Interleukin-11 (rhIL-11)” NCT06759636 ↗ |
| Known as | rhIL-11 | “Recombinant Human Interleukin-11 (rhIL-11)” NCT00040521 ↗1“Recombinant Human Interleukin-11 (rhIL-11)” NCT06759636 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-11 (rhIL-11)” NCT00040521 ↗ |
| Route | Subcutaneous | “interleukin-11 (IL-11) subcutaneously (SQ) on days 1-10” NCT00004157 ↗ |